European Pharmaceutical Review
SEPTEMBER 28, 2023
There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.
pharmaphorum
JUNE 21, 2022
While proponents argue waiving IP on COVID-19 vaccines would better enable low- and middle-income countries to inoculate their populations, the pharma industry has called the proposals “unnecessary and harmful to innovation”. An IP waiver does not address inequitable access to COVID-19 vaccines and will put global health security at risk.”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 16, 2022
Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.
European Pharmaceutical Review
OCTOBER 24, 2022
Three trade bodies representing vaccine creators and manufacturers are endorsing The Berlin Declaration framework , a proposal that outlines how the industry would reserve an allocation of real-time vaccine production for swift distribution to priority populations in lower-income countries in future pandemics.
European Pharmaceutical Review
FEBRUARY 10, 2025
AstraZeneca has scrapped its planned 450 million expansion of a vaccine manufacturing facility in Liverpool, UK, citing economic factors and reduced government funding. The post AstraZeneca cancels 450m Liverpool vaccine facility expansion appeared first on European Pharmaceutical Review.
Pharma Mirror
MAY 31, 2023
In the face of increasing global health challenges, the development and production of vaccines have become paramount. One critical aspect is the ability to scale up manufacturing processes to meet the growing demand for viral vector-based vaccines.
Express Pharma
SEPTEMBER 13, 2024
The world massively relies on the developments that continue to take place in the pharmaceutical industry to experience an improved quality of life. Therefore, to successfully implement CM in every pharma manufacturing facility, the key focus should be key investments, advancing scientific and technical knowledge, and additional incentives.
Expert insights. Personalized for you.
98 
Let's personalize your content